natgillin/translations-raw huggingface dataset:
No dose adjustment is required in patients aged 65 years and older.
Nije potrebno prilagođavati dozu kod bolesnika u dobi od 65 ili više godina.
No dose adjustment is required in patients with creatinine clearance above 30 ml/min.
U bolesnika sa klirensom kreatinina iznad 30 ml/min nije potrebna prilagodba doze.
No dose adjustment is required in patients with hepatic impairment (see section 5.2).
Nema potrebe za prilagođavanjem doze u bolesnika s oštećenjem jetre (vidjeti dio 5.2).
No dose adjustment is required in patients with hepatic impairment (see section 5.2).
U bolesnika s oštećenjem funkcije jetre nije potrebna prilagodba doze (vidjeti dio 5.2).
No dose adjustment is required in patients with hepatic impairment.
Nije potrebna prilagodba doze kod bolesnika s oštećenjem funkcije jetre.
No dose adjustment is required in patients with impaired renal function (see section 5.2).
Nije potrebno prilagođavanje doze u bolesnika s oštećenom funkcijom bubrega (vidjeti dio 5.2).
No dose adjustment is required in patients with impaired renal function at creatinine clearance
Nije potrebna prilagodba doze u bolesnika s oštećenjem bubrežne funkcije s klirensom kreatinina
No dose adjustment is required in patients with mild hepatic impairment.
Nije potrebna prilagodba doze u bolesnika s blagim oštećenjem funkcije jetre.
No dose adjustment is required in patients with mild hepatic impairment.
Nije potrebno prilagođavanje doze u bolesnika s blagim oštećenjem jetre.
No dose adjustment is required in patients with mild hepatic impairment.
Nije potrebno prilagođavati dozu u bolesnika s blagim oštećenjem funkcije jetre.
No dose adjustment is required in patients with mild or moderate renal impairment (see also section 5.2).
Nije potrebna prilagodba doze u bolesnika s blagim ili umjerenim oštećenjem funkcije bubrega (vidjeti također dio 5.2).
No dose adjustment is required in patients with mild renal impairment (creatinine clearance 50 to 80 ml/min; see section 5.2).
Nije potrebno prilagođavanje doze kod bolesnika s blagim oštećenjima bubrega (klirens kreatinina od 50 do 80 ml/min; vidjeti dio 5.2).
No dose adjustment is required in patients with mild to moderate hepatic impairment.
Nije potrebno prilagoĎavati dozu u bolesnika s blagim i umjerenim oštećenjem jetrene funkcije.
No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance [CrCl] 30-89 mL/min) (see section 5.2).
Nije potrebno prilagođavati dozu u bolesnika s blagim do umjerenim oštećenjem funkcije bubrega (klirens kreatinina [CrCl] 30-89 ml/min) (vidjeti dio 5.2).
No dose adjustment is required in patients with mild to moderate renal impairment who are receiving pirfenidone.
U bolesnika s blagim do umjerenim oštećenjem funkcije bubrega koji se liječe pirfenidonom nije potrebno prilagođavati dozu.
No dose adjustment is required in patients with mild-to-moderate renal impairment (30-70 ml/min creatinine clearance) (see sections 4.4 and 5.2).
U bolesnika s blago do umjereno oštećenom funkcijom bubrega (klirens kreatinina 30-70 ml/min) dozu ne treba prilagođavati (vidjeti dijelove 4.4 i 5.2).
No dose adjustment is required in patients with renal impairment (see section 5.2).
U bolesnika s oštećenjem funkcije bubrega nije potrebna prilagodba doze (vidjeti dio 5.2).
No dose adjustment is required in patients with renal impairment (see sections 4.4 and 5.2).
U bolesnika s oštećenjem bubrega nije potrebna prilagodba doze (vidjeti dijelove 4.4 i 5.2).
No dose adjustment is required in patients with renal impairment (see sections 4.4 for recommendations relating to monitoring of calcium).
Nije potrebna prilagodba doze u bolesnika s oštećenjem funkcije bubrega (vidjeti dio 4.4 za preporuke vezane uz praćenje razine kalcija).
No dose adjustment is required in patients with renal impairment, including those patients with end-stage renal disease.
Nije potrebna prilagodba doze kod bolesnika s oštećenjem funkcije bubrega, uključujući i bolesnike u terminalnoj fazi bubreţne bolesti.
No dose adjustment is required in patients with renal impairment.
Nije potrebna prilagodba doze kod bolesnika s oštećenjem funkcije bubrega.
No dose adjustment is required in patients with renal impairment.
U bolesnika sa smanjenjem bubrežne funkcije ne treba prilagoditi dozu.
No dose adjustment is required in RA patients.
Nije potrebna prilagodba doze u bolesnika s RA.
No dose adjustment is required in relation to age (see section 5.2)
Prilagodba doze nije potrebna vezano uz dob (vidjeti dio 5.2).
No dose adjustment is required in relation to age (see section 5.2).
Prilagodba doze nije potrebna vezano uz dob (vidjeti dio 5.2).
No dose adjustment is required in the elderly (see section 5.2).
Nije potrebno prilagođavanje doze kod starijih bolesnika (vidjeti dio 5.2)
No dose adjustment is required in the elderly population.
Nije potrebna prilagodba doze u starijih bolesnika.
No dose adjustment is required in the elderly.
Nije potrebna prilagodba doze u starijih osoba.
No dose adjustment is required in this population (see section 5.2).
Nema potrebe za prilagođavanjem doze u toj populaciji (vidjeti dio 5.2).
No dose adjustment is required on the basis of patient age (see section 5.2).
Nije potrebna prilagodba doze s obzirom na dob bolesnika (vidjeti dio 5.2).
No dose adjustment is required when co-administering with probenecid in patients with normal renal function.
Nije potrebna prilagodba doze ako se Tamiflu primjenjuje istodobno s probenecidom u bolesnika s normalnom funkcijom bubrega.
No dose adjustment is required when initiating treatment with Zydelig in patients with mild or moderate hepatic impairment, but an intensified monitoring of adverse reactions is recommended (see sections 4.4 and 5.2).
Nije potrebna prilagodba doze za početak liječenja Zydeligom u pacijenata s blagim ili umjerenim oštećenjem funkcije jetre, ali se preporučuje pojačani nadzor zbog nuspojava (vidjeti dijelove 4.4 i 5.2).
No dose adjustment is required when NovoThirteen is used in paediatric patients and the dose of 35 IU/kg body weight should be used (see section 5.2 ‘Paediatric population’).
Nije potrebno prilagođavanje doze kad se NovoThirteen koristi u pedijatrijskih bolesnika te je potrebno primjenjivati dozu od 35 IU/kg tjelesne težine (vidjeti dio 5.2 ‘Pedijatrijska populacija’).
No dose adjustment is required when Stribild is co-administered with telaprevir.
Prilagodba doze nije potrebna kada se Stribild istovremeno primjenjuje s telaprevirom.
No dose adjustment is required when Tybost is co-administered with telaprevir.
Prilagodba doze nije potrebna kada se Tybost istovremeno primjenjuje s telaprevirom.
No dose adjustment is required,
Nije potrebna prilagodba doze,
No dose adjustment is required, however, BUCCOLAM should be used with caution in patients with chronic renal failure as elimination of midazolam may be delayed and the effects prolonged. (see section 4.4)
Nije potrebno prilagođavati dozu, ali BUCCOLAM treba oprezno primjenjivati u bolesnika s kroničnim oštećenjem bubrežne funkcije jer eliminacija midazolama može biti usporena a učinci produljeni (vidjeti dio 4.4).
No dose adjustment is required, unless there is evidence of moderate or severe renal impairment.
Nije potrebna prilagodba doze osim ako nema dokaza o umjerenom ili teškom oštećenju bubrežne
No dose adjustment is required, unless there is evidence of moderate or severe renal impairment.
Nije potrebna prilagodba doze osim ako nema dokaza o umjerenom ili teškom oštećenju bubrežne funkcije.
No dose adjustment is required.
Nema preporučene prilagodbe doziranja.
No dose adjustment is required.
Nije ispitano.
No dose adjustment is required.
Nije potrebno prilagođavanje doze.
No dose adjustment is required.
Nije potrebno prilagođavati dozu
No dose adjustment is required.
Nije potrebno prilagođivati dozu.
No dose adjustment is required.
Usprkos tome, prilagođivanje doze nije potrebno.
No dose adjustment is required. (see section 5.2).
Nije potrebna prilagodba doze (vidjeti dio 5.2).
No dose adjustment is suggested but caution is adviced in patients with moderate hepatic impairment.
Nije predložena prilagodba doze, ali se savjetuje oprez kod bolesnika s umjerenim oštećenjem jetre.
No dose adjustment is warranted for elderly patients (see section 5.2).
Nije potrebna prilagodba doze u starijih pacijenata (vidjeti dio 5.2).
No dose adjustment necessary
Nije potrebno prilagođavanje doze.
No dose adjustment necessary
Nije potrebno prilagođavati dozu
No dose adjustment necessary (see section 5.2).
Nije potrebno prilagođavati dozu (vidjeti dio 5.2).
No dose adjustment necessary (see sections 4.4 and 5.2).
Nije potrebno prilagođavati dozu (vidjeti dijelove 4.4 i 5.2).
No dose adjustment necessary.
Nije potrebno prilagođavati dozu.
No dose adjustment needed
Makismalna dnevna doza rosuvastatina smije biti
No dose adjustment needed for sofosbuvir
prilagođavati dozu
No dose adjustment needed for Viekirax with or without dasabuvir.
Nije potrebna prilagodba doze lijeka Viekirax primijenjenog s
No dose adjustment needed for Viekirax with or without dasabuvir.
Nije potrebna prilagodba doze za lijek Viekirax u kombinaciji s dasabuvirom ili bez njega.
No dose adjustment needed for Viekirax with or without dasabuvir.
Nije potrebno prilagođavati
No dose adjustment needed for Viekirax.
doze lijeka Viekirax.
No dose adjustment of
Ne preporučuje se
No dose adjustment of
Nije potrebno prilagođavati
No dose adjustment of BRINAVESS is required for these conditions, nor on the basis of age, serum creatinine or CYP2D6 metaboliser status.
Nije potrebno prilagođavati dozu lijeka BRINAVESS zbog navedenih stanja kao ni temeljem dobi, vrijednosti kreatinina u serumu ili statusa metabolizacije putem CYP2D6.
No dose adjustment of Copalia HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m2).
U bolesnika s blagim do umjerenim oštećenjem bubrega (GFR >30 ml/min/1,73 m2) dozu Copalia HCT-a nije potrebno prilagođavati.
No dose adjustment of CRESEMBA is necessary when co- administered with strong CYP3A4/5 inhibitors, however caution is advised as adverse drug reactions may increase (see section 4.5).
Nije potrebno prilagoĎavati dozu lijeka CRESEMBA kada se primjenjuje istodobno sa snaţnim inhibitorima CYP3A4/5, meĎutim preporučuje se oprez, jer se nuspojave na lijek mogu povećati (vidjeti dio 4.5).
No dose adjustment of CRESEMBA is necessary when co-administered with strong CYP3A4/5 inhibitors, however caution is advised as adverse drug reactions may increase (see section 4.4).
Nije potrebna prilagodba doze lijeka CRESEMBA kada se primjenjuje istodobno sa snaţnim inhibitorima CYP3A4/5, meĎutim preporučuje se oprez, jer se nuspojave na lijek mogu pojačati (vidjeti dio 4.4).
No dose adjustment of Dafiro HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m2).
U bolesnika s blagim do umjerenim oštećenjem bubrega (GFR >30 ml/min/1,73 m2) dozu Dafiro HCT-a nije potrebno prilagođavati.
No dose adjustment of Daklinza is required for patients with mild (Child-Pugh A, score 5-6), moderate (Child-Pugh B, score 7-9) or severe (Child-Pugh C, score ≥10) hepatic impairment (see sections 4.4 and 5.2).
Nije potrebno prilagođavati dozu u bolesnika s blagim (Child-Pugh stadij A, vrijednost: 5-6), umjerenim (Child-Pugh stadij B, vrijednost: 7-9) ili teškim (Child-Pugh stadij C, vrijednost: ≥ 10) oštećenjem jetrene funkcije (vidjeti dijelove 4.4 i 5.2).
No dose adjustment of Daklinza or raltegravir is required.
Nije potrebno prilagođavati dozu lijeka Daklinza niraltegravira.
No dose adjustment of Daklinza or simeprevir is required.
Nije potrebno prilagođavati dozu lijeka Daklinza ni simeprevira.
No dose adjustment of Descovy is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.
Nije potrebna prilagodba doze lijeka Descovy u bolesnika s blagim (Child-Pugh, stadij A) ili umjerenim (Child-Pugh stadij B) oštećenjem funkcije jetre.
No dose adjustment of digoxin is required based on these results.
Na osnovi ovih rezultata, nije potrebno prilagođavanje doze digoksina.
No dose adjustment of efavirenz is required.
Nije potrebno prilagođavati dozu efavirenza.
No dose adjustment of elvitegravir or cobicistat is necessary for patients with mild to moderate hepatic impairment.
Nije potrebna prilagodba doze elvitegravira i kobicistata za pacijente s blagim do umjerenim oštećenjem funkcije jetre.
No dose adjustment of elvitegravir or cobicistat is necessary for patients with renal impairment.
Nije potrebna prilagodba doze elvitegravira i kobicistata za pacijente s oštećenjem funkcije bubrega.
No dose adjustment of Empliciti is required for patients with mild (CrCl = 60 - 89 mL/min), moderate (CrCl = 30 - 59 mL/min), severe (CrCl < 30 mL/min) renal impairment or end stage renal disease requiring dialysis (see section 5.2).
Nije potrebno prilagođavati dozu lijeka Empliciti u bolesnika s blagim (CrCl = 60 – 89 ml/min), umjerenim (CrCl = 30 – 59 ml/min) ili teškim (CrCl < 30 ml/min) oštećenjem funkcije bubrega, kao ni u bolesnika u terminalnoj fazi bubrežne bolesti kojima je potrebna dijaliza (vidjeti dio 5.2).
No dose adjustment of Epclusa is required for patients with mild or moderate renal impairment.
Ne preporučuje se prilagodba doze lijeka Epclusa u pacijenata s blagim ili umjerenim oštećenjem bubrega.
No dose adjustment of Epclusa is required for patients with mild or moderate renal impairment.
Nije potrebna prilagodba doze lijeka Epclusa u pacijenata s blagim ili umjerenim oštećenjem bubrega.
No dose adjustment of Epclusa or ciclosporin is required.
Nije potrebna prilagodba doze lijeka Epclusa ili ciklosporina.
No dose adjustment of Epclusa or dolutegravir is required.
Nije potrebna prilagodba doze lijeka Epclusa ili dolutegravira.
No dose adjustment of Epclusa or elvitegravir/ cobicistat/ emtricitabine/ tenofovir alafenamide fumarate is required.
Nije potrebna prilagodba doze lijeka Epclusa ili elvitegravira/kobicistata/ emtricitabina/ tenofoviralafenamidfumarata.
No dose adjustment of Epclusa or elvitegravir/ cobicistat/emtricitabine/ tenofovir disoproxil fumarate is required.
Nije potrebna prilagodba doze lijeka Epclusa ili elvitegravira/kobicistata/ emtricitabina/ tenofovirdizoproksilfumarata.
No dose adjustment of Epclusa or emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate is required.
Nije potrebna prilagodba doze lijeka Epclusa ili emtricitabina/rilpivirina/ Tenofovirdizoproksilfumarata.
No dose adjustment of Epclusa or methadone is required.
Nije potrebna prilagodba doze lijeka Epclusa ili metadona.
No dose adjustment of Epclusa or tacrolimus is required.
Nije potrebna prilagodba doze lijeka Epclusa ili takrolimusa.
No dose adjustment of Epclusa, darunavir (ritonavir boosted) or emtricitabine/ tenofovir disoproxil fumarate is required.
Nije potrebna prilagodba doze lijeka Epclusa, darunavira (pojačanog ritonavirom) ili emtricitabina/ tenofovirdizoproksilfumarata.
No dose adjustment of Epclusa, lopinavir (ritonavir boosted) or emtricitabine/ tenofovir disoproxil fumarate is required.
Nije potrebna prilagodba doze lijeka Epclusa, darunavira (pojačanog lopinavirom) ili emtricitabina/ tenofovirdizoproksilfumarata.
No dose adjustment of Eviplera is required in patients with mild or moderate hepatic impairment.
Nije potrebna prilagodba doze lijeka Eviplera u pacijenata s blagim ili umjerenim oštećenjem jetre.
No dose adjustment of Eviplera is suggested but caution is advised in patients with moderate hepatic impairment.
Ne predlaže se prilagodba doze lijeka Eviplera, ali se savjetuje oprez u pacijenata s umjerenim oštećenjem jetre.
No dose adjustment of Exviera is required for patients with mild, moderate, or severe renal impairment (see section 5.2).
Nije potrebno prilagođavati dozu lijeka Exviera u bolesnika s blagim, umjerenim ili teškim oštećenjem bubrežne funkcije (vidjeti dio 5.2).
No dose adjustment of Exviera is required in patients with mild hepatic impairment (Child-Pugh A).
Nije potrebno prilagođavati dozu lijeka Exviera u bolesnika s blagim oštećenjem jetrene funkcije (Child-Pugh stadij A).
No dose adjustment of Genvoya is required in elderly patients (see sections 5.1 and 5.2).
Nije potrebna prilagodba doze lijeka Genvoya u starijih bolesnika (vidjeti dijelove 5.1 i 5.2).
No dose adjustment of Genvoya is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.
Nije potrebna prilagodba doze lijeka Genvoya u bolesnika s blagim (Child-Pugh, stadij A) ili umjerenim (Child-Pugh stadij B) oštećenjem funkcije jetre.
No dose adjustment of Glybera is necessary in the elderly population.
Nije potrebno prilagođavati dozu Glybere u starije populacije.
No dose adjustment of Glybera is required.
Nije potrebno podešavati dozu Glybere.
No dose adjustment of lumacaftor/ivacaftor
Može biti potrebna viša doza flukonazola
No dose adjustment of lumacaftor/ivacaftor
Ne preporučuje se prilagodba doze
No dose adjustment of lurasidone is required in patients with mild renal impairment.
Nije potrebno prilagođavati dozu lurasidona u bolesnika s blagim oštećenjem bubrega.
No dose adjustment of methadone is required.
Nije potrebno prilagođavati dozu.
No dose adjustment of methadone is required.
Nije potrebno prilagođivati dozu.
No dose adjustment of Odefsey is required in elderly patients (see section 5.2).
Nije potrebna prilagodba doze lijeka Odefsey u starih bolesnika (vidjeti dio 5.2).
No dose adjustment of OLYSIO is required in HCV/HIV-1 co-infected patients (see sections 4.8, 5.1 and 5.2).
Nije potrebna prilagodba doze za lijek OLYSIO u bolesnika s koinfekcijom HCV-om i HIV-om-1 (vidjeti dijelove 4.8, 5.1 i 5.2).
No dose adjustment of pomalidomide is required for patients with renal impairment.
U bolesnika s oštećenjem funkcije bubrega nije potrebna prilagodba doze pomalidomida.
No dose adjustment of ribavirin is required.
Nije potrebno prilagođavati dozu.
No dose adjustment of saquinavir recommended.
manjenje doze digoksina.
No dose adjustment of Sovaldi is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh-Turcotte [CPT] class A, B or C) (see section 5.2).
Nije potrebna prilagodba doze Sovaldija u bolesnika s blagim, umjerenim ili teškim oštećenjem jetre (Child-Pugh-Turcotte [CPT] stadij A, B ili C) (vidjeti dio 5.2).
No dose adjustment of Stribild is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment (see sections 4.2 and 5.2).
U pacijenata s blagim (Child-Pugh stadij A) ili umjerenim (Child-Pugh stadij B) oštećenjem jetre nije potrebno prilagođavati dozu Stribilda (vidjeti dijelove 4.2 i 5.2).
No dose adjustment of Stribild is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.
Nije potrebna prilagodba doze Stribilda u pacijenata s blagim (Child-Pugh, stadij A) ili umjerenim (Child-Pugh stadij B) oštećenjem jetre.
No dose adjustment of Tasmar is recommended for elderly patients.
Nije preporučena prilagodba doze Tasmara za starije bolesnike.
No dose adjustment of temsirolimus is recommended for patients with advanced renal cell carcinoma (RCC) and mild to moderate hepatic impairment.
Ne preporučuje se prilagodba doze temsirolimusa u bolesnika s uznapredovalim karcinomom bubrežnih stanica (RCC) i blagim do umjerenim oštećenjem funkcije jetre.
No dose adjustment of temsirolimus is recommended in patients with renal impairment.
Ne preporučuje se prilagodba doze temsirolimusa u bolesnika s oštećenjem funkcije bubrega.
No dose adjustment of Tybost is necessary for patients with mild to moderate hepatic impairment.
Nije potrebna prilagodba doze lijeka Tybost za pacijente s blagim do umjerenim oštećenjem funkcije jetre.
No dose adjustment of Tybost is required for patients with renal impairment, including those with severe renal impairment.
Nije potrebna prilagodba doze lijeka Tybost za pacijente s oštećenjem bubrega uključujući i one s teškim oštećenjem bubrega.
No dose adjustment of Tybost is required in patients with mild (Child-Pugh Class A) or moderate hepatic impairment (Child-Pugh Class B).
Nije potrebna prilagodba doze lijeka Tybost u pacijenata s blagim (Child-Pugh stadij A) ili umjerenim (Child-Pugh stadij B) oštećenjem jetre.
No dose adjustment of Tybost is required.
Nije potrebna prilagodba doze lijeka Tybost.
No dose adjustment of Victrelis is required in patients with any degree of renal impairment (see section 5.2).
Nije potrebno prilagođavati dozu lijeka Victrelis u bolesnika s bilo kojim stupnjem oštećenja funkcije bubrega (vidjeti dio 5.2).
No dose adjustment of Viekirax is required for patients with mild, moderate, or severe renal impairment (see section 5.2).
Nije potrebno prilagođavati dozu lijeka Viekirax u bolesnika s blagim, umjerenim ili teškim oštećenjem bubrežne funkcije (vidjeti dio 5.2).
No dose adjustment of Viekirax is required in patients with mild hepatic impairment (Child-Pugh A).
Nije potrebno prilagođavati dozu lijeka Viekirax u bolesnika s blagim oštećenjem jetrene funkcije (Child-Pugh stadij A).
No dose adjustment of ZEPATIER is required for elderly patients (see sections 4.4 and 5.2).
Nije potrebno prilagođavati dozu lijeka ZEPATIER u starijih bolesnika (vidjeti dijelove 4.4 i 5.2).
No dose adjustment of ZEPATIER is required in patients with mild, moderate, or severe renal impairment (including patients receiving haemodialysis or peritoneal dialysis) (see section 5.2).
Nije potrebno prilagođavati dozu lijeka ZEPATIER u bolesnika s blagim, umjerenim ili teškim oštećenjem funkcije bubrega (uključujući bolesnike na hemodijalizi ili peritonejskoj dijalizi) (vidjeti dio 5.2).
No dose adjustment or special considerations are anticipated for patients with renal impairment (see section 5.2).
Ne predviđaju se prilagođavanje doze ni posebna upozorenja za bolesnike s oštećenjem funkcije bubrega (vidjeti dio 5.2).
No dose adjustment required
Nije potrebno prilagođavati
No dose adjustment required (see section 5.2).
Nije potrebno prilagođavati dozu (vidjeti dio 5.2).
No dose adjustment required for ISENTRESS or boceprevir.
Nije potrebno prilagođavati dozu lijeka ISENTRESS ili boceprevira.
No dose adjustment required for ISENTRESS or etravirine.
Nije potrebno prilagođavati dozu lijeka ISENTRESS ili etravirina.
No dose adjustment required for ISENTRESS or maraviroc.
Nije potrebno prilagođavati dozu lijeka ISENTRESS ili maraviroka.
No dose adjustment required for ISENTRESS or methadone.
Nije potrebno prilagođavati dozu lijeka ISENTRESS ili metadona.
No dose adjustment required for ISENTRESS or tenofovir disoproxil fumarate.
Nije potrebno prilagođavati dozu lijeka ISENTRESS ili tenofovir dizoproksil fumarata.
No dose adjustment required for ISENTRESS.
Nije potrebno prilagođavati dozu lijeka ISENTRESS.
No dose adjustments are considered necessary (see section 5.2).
Nije potrebno prilagođavati dozu (vidjeti dio 5.2).
No dose adjustments are expected to be required.
Ne očekuje se potreba za prilagodbom doze.
No dose adjustments are necessary in these patients.
Nije potrebno prilagođavati dozu u tih bolesnika.
No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease.
Nisu potrebne prilagodbe doze kod bolesnika s presađenim bubregom i teškim oštećenjem jetrenog parenhima.
No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease.
Nisu potrebne prilagodbe terapijske doze kod bolesnika s presađenim bubregom i teškim oštećenjem jetrenog parenhima.
No dose adjustments are needed in patients experiencing delayed renal graft function post-operatively. (see section 5.2).
Kod bolesnika kod kojih nakon presađivanja dolazi do odgođene funkcije presađenog bubrega nisu potrebne prilagodbe terapijske doze (vidjeti dio 5.2).
No dose adjustments are needed in patients with mild or moderate impairment (see section 4.4).
Nije potrebna prilagodba doze u bolesnika s blagim ili umjerenim oštećenjem (vidjeti dio 4.4).
No dose adjustments are recommended in obese or low body weight patients (see sections 4.4 and 5.2).
Ne preporučuje se prilagođavanje doze u pretilih bolesnika ili bolesnika niske tjelesne težine (vidjeti dio 4.4 i 5.2)